The team will develop a fully automated, benchtop, continuous-flow system for end-to-end production of RNA drug products, combining proprietary technologies from a consortium of expert organizations. Its core comprises four integrated, modular units: Cell-Free Enzymatic DNA Production, Continuous-Flow RNA Synthesis, Lipid Nanoparticle (LNP) Formulation, and Fill-Finish. The team will also develop an integrated quality control system for lot release, combining in-line, at-line and off-line characterization of drug product, fully autonomous and automated using proprietary software, robotics and the most advanced measurement technologies available.